Loading news...
Shares of Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation
Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PALO ALTO, Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present at the 44th Annual J.P.
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shares traded down 5.8% during mid-day trading on Friday. The stock traded as low as $29.27 and last traded at $29.2750. 145,497 shares changed hands during trading, a decline of 76% from the average session volume of 603,202 shares. The stock had previously closed at $31.08.
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $29.49 and last traded at $28.61, with a volume of 1282200 shares changing hands. The stock had previously closed at $26.00. Analysts Set New Price Targets Several equities research
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shares gapped up prior to trading on Monday after an insider bought additional shares in the company. The stock had previously closed at $26.00, but opened at $27.95. Kodiak Sciences shares last traded at $28.2410, with a volume of 141,605 shares. Specifically, Director Bros. Advisors Lp Baker
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) Director Bros. Advisors Lp Baker acquired 2,608,696 shares of the firm's stock in a transaction dated Thursday, December 18th. The stock was bought at an average price of $23.00 per share, with a total value of $60,000,008.00. Following the purchase, the director directly owned 18,358,772 shares in
PALO ALTO, Calif. , Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share.
PALO ALTO, Calif. , Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the pricing of an upsized underwritten public offering of 6,956,522 shares of its common stock at a price to the public of $23.00 per share.
PALO ALTO, Calif. , Dec. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that it has commenced an underwritten public offering of 6,000,000 of shares of its common stock.
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
PALO ALTO, Calif. , Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025.
PALO ALTO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that Victor Perlroth, M.D.
Meaningful vision gains are rapidly achieved as early as week 4 and showed continued improvement in best corrected visual acuity (BCVA) through week 20, with more than half of patients achieving improvement of 3-lines or more on the eye chart (≥15 letter gain). ≥90% of patients in the top two dose levels achieved and sustained real dryness of the retina, as demonstrated by absence of intraretinal fluid (IRF) as well as subretinal fluid (SRF), key markers of disease activity.
Alphabet (GOOGL) spiked into its earnings this week, and @stockstotrade's Tim Bohen believes the Google parent company has much more room to run. He explains his bull case that rides on A.I.
Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain) A single dose of KSI-101 resulted in the majority of patients achieving resolution of intra-retinal and sub-retinal fluid and over 90% of patients achieved retinal dryness by Week 8 The Phase 3 PEAK and PINNACLE studies of KSI-101 are actively enrolling, testing the top two dose levels (5 mg and 10 mg) in patients with MESI PALO ALTO, Calif. , Sept. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today new data from the APEX study of KSI-101 presented at the Retina Society 58th Annual Scientific Meeting in Chicago, Illinois.
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
PALO ALTO, Calif. , Sept. 2, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced participation in two upcoming scientific meetings: The 25th EURetina Congress and The Retina Society 58th Annual Scientific Meeting.
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its interim results for the six months ended June 30, 2025.